Brought to you by 
Amakem spins off from Devgen; brings in €1.5mm in seed money
01 Apr 2010
Executive Summary
Devgen NV (now focused on crop enhancement technology) has spun off the assets and IP from its former pharma division into Amakem NV (respiratory and ophthalmic compounds). The newly formed company simultaneously raised €1.5mm ($2mm) in seed money from lead investor Lombard Risk Management (LRM), Life Sciences Research Partners, and Vlaams Innovatiefonds--Flemish Innovation Fund (VINNOF). Devgen will retain a 21% stake in Amakem.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amakem spins off from Devgen; brings in €1.5mm in seed money
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice